People · Operator
Named in public records as an officer, director or promoter · active 2026–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allyx Therapeutics, Inc. | — | Biotechnology | Series A | $13.2M | $7.9M | 2026 |
Timothy A Siegert at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Timothy A Siegert on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Bloch | 1 | 15 |
| Paul Fonteyne | 1 | 5 |
| Robert A Bettigole | 1 | 3 |
| Gregory P Ho | 1 | 2 |
| Jennifer A Gabler | 1 | 1 |
| Stephen Strittmatter | 1 | 1 |
| Paul P. Fonteyne | 1 | 1 |
| Timothy P. Siegert | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.